Alison Brand AM, MD, MMEd, FRCS(C), FRANZCOG, CGO, is Clinical Professor in the Faculty of Medicine and Health at the University of Sydney and Director of Gynaecological Oncology at Westmead Hospital, Sydney. She completed her Masters of Medical Education through the University of Sydney. As a certified gynaecologic oncologist, she treats women with gynaecological cancers of the ovary, uterus, cervix, vulva, and vagina, precancerous conditions such as cervical dysplasia, pelvic masses, and performs complex pelvic surgery, both laparoscopic and open. She has a special interest in familial cancer conditions including BRCA and Lynch syndrome (HNPCC). Professor Brand served as the first female Chair of the Australian New Zealand Gynaecological Oncology Group (ANZGOG) from 2012 to 2018, doubling membership, establishing the OASIS Initiative, launching a fund for new research grants, and expanding the clinical trials portfolio. She is immediate Past-Chair of the Gynecologic Cancer Intergroup (GCIG), an umbrella of 33 international trials groups. She has held advisory and board positions with Cancer Australia, Clinical Oncology Society of Australia, and GCIG, contributed to national guidelines on endometrial cancer, ovarian cancer, and cervical cancer screening, and received NHMRC and Cancer Australia research grants.

Her research specializations include surgical trials, pragmatic trials, and clinical quality indicators in gynaecological oncology. Key publications are 'Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial' (Janda et al., 2017), 'Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial' (Janda et al., 2010), 'Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes' (Hodgkinson et al., 2007), 'Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma' (Kondrashova et al., 2018), and 'The molecular origin and taxonomy of mucinous ovarian carcinoma' (Cheasley et al., 2019). In 2021, she received the Member of the Order of Australia (AM) for significant service to medicine, gynaecology, and medical organisations. She is an invited speaker at national and international meetings, organises gynaecological cancer scientific meetings, peer reviews for oncology journals, and mentors in the field.

Professional Email: alison.brand@health.nsw.gov.au